Skip to main content

Table 1 Baseline clinical characteristics before sorafenib treatment and response rates after treatment

From: Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study

Characteristics before sorafenib treatment
(n = 132)
Values*
Age, years 59 (50–72)
Male, n (%) 96 (73)
Age > 60 years, n (%) 59 (45)
Nephrectomy, n (%) 132 (100)
Stage at RCC diagnosis, n (%)
 Unknown 32 (24)
 1 4 (3)
 2 11 (8)
 3 32 (24)
 4 53 (41)
Karnofsky performance status scores
 100 1 (1)
 90 82 (62)
 80 49 (37)
 High blood pressure, n (%) 44 (33)
 Hypothyroidism, n (%) 8 (6)
Site of metastasis
 Lung, n (%) 70 (53)
 Bone, n (%) 17 (13)
 Liver, n (%) 18 (14)
 Lymph node, n (%) 12 (9)
First-line and concomitant treatments
 Sunitinib, n (%) 132 (100)
 Interferon, n (%) 3 (2)
 Radiotherapy, n (%) 27 (20)
 Zoledronic acid, n (%) 2 (2)
Risk status, % (n)**
 Favorable risk 48 (36)
 Intermediate risk 81 (61)
 High risk 3 (23)
 Hemoglobin, g/dL 13.9 ± 1.8
 Leucocytes, 109/L 6.5 (5.3–8.2)
 Neutrophils, 109/L 3.9 (2.6–5.0)
 Platelets, 109/L 235 (186–310)
 Albumin-adj calcium, g/dL 9.5 (9.0–9.8)
 LDH, mg/dL 178 (151–234)
Response rates after sorafenib treatment
 Complete Response, n (%) 3 (2)
 Partial Response, n (%) 11 (8)
 Stable Disease, n (%) 13 (10)
 Progressive Disease, n (%) 105 (80)
  1. * Continuous variables are expressed as mean ± SD or as median (25th–75th percentile), categorical variables are expressed as n (%). **Risk status was classified according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC model), in which favorable risk is equivalent to no factors, intermediate risk, 1–2 factors, and high risk, 3–6 factors [18]. LDH Lactate dehydrogenase, Albumin-adj Albumin-adjusted
\